IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
- Registration Number
- NCT03757234
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Brief Summary
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.
- Detailed Description
This was a randomized (1:1:1:1:1), double-blind, double-dummy, adaptive designed, Phase 2 study. Based on review of the efficacy and microbiology data, the DMC modified the randomization algorithm, and no further participants were enrolled in the following treatment arms after May 2019: the omadacycline 200 iv/100 iv, omadacycline 200 iv/300 po or 100 iv, and omadacycline 200 iv/450 po or 100 iv arms. After this change, participants were randomized in a 1:1 ratio to either the omadacycline 200 iv/200 iv or levofloxacin arms.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 201
- Female participants, age 18-65 years who have signed the informed consent form
- Must have a qualifying acute pyelonephritis
- Participants must not be pregnant at the time of enrollment
- Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug
- Must be able to comply with all of the requirements of the study
- Males
- Symptoms of acute pyelonephritis present for longer 7 days prior to randomization
- Infections that require antibacterial treatment for greater than 14 days
- Evidence of suspected non-renal source of infections, vaginitis, or sexually transmitted infection
- Evidence of significant immunological disease
- Evidence of liver impairment or disease
- Evidence of unstable cardiac disease
- Severe renal disease or requirement for dialysis
- Evidence of septic shock
- Has a history of hypersensitivity or allergic reaction to any tetracycline or to levofloxacin
- Has received an investigational drug within the past 30 days
- Participants who are pregnant or nursing
- Unable or unwilling to comply with the protocol requirements
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Omadacycline 200 iv/300 po or 100 iv Omadacycline On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state. Omadacycline 200 iv/200 iv Omadacycline On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. Omadacycline 200 iv/100 iv Omadacycline On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. Omadacycline 200 iv/450 po or 100 iv Omadacycline On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state. Levofloxacin 750 iv/750 po or iv Levofloxacin On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
- Primary Outcome Measures
Name Time Method Number of Participants With Resolution of All AP Signs and Clinical Symptoms at PTE Visit (ITT Population) Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug). Participants recorded their assessments using the Modified Patient Symptom Assessment Questionnaire (mPSAQ), a 6-item questionnaire that assessed the levels of 'severity' and 'bothersomeness' for six pyelonephritis signs and symptoms. The sub-scale responses were recorded as 'did not have', 'mild', 'moderate', and 'severe' for 'severity'; and 'not at all', 'a little', 'moderately', and 'a lot' for 'bothersomeness', both scored 0-3. Total scores were calculated by summing the non-missing scores of the 6 items, divided by the number of non-missing items, and then multiplied by 6. For each sub-scale, the total score ranged from 0 (least Severe/ least bothersome) and 18 (worst severity/most bothersome). Number of participants with resolution of all symptoms, without occurrence of new symptoms is reported. Resolution was defined as absence of all baseline symptoms.
Number of Participants With No Worsening and Absence of New AP Signs and Clinical Symptoms at PTE Visit (ITT Population) Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug). Participants recorded their assessments using the mPSAQ, a 6-item questionnaire that assessed the levels of 'severity' and 'bothersomeness' for six pyelonephritis signs and symptoms. The sub-scale responses were recorded as 'did not have', 'mild', 'moderate', and 'severe' for 'severity'; and 'not at all', 'a little', 'moderately', and 'a lot' for 'bothersomeness', both scored 0-3. Total scores were calculated by summing the non-missing scores of the 6 items, divided by the number of non-missing items, and then multiplied by 6. For each sub-scale, the total score ranged from 0 (least Severe/ least bothersome) and 18 (worst severity/most bothersome). Number of participants with no worsening and absence of AP signs and clinical symptoms is reported. No worsening meant that each question score is same or better at post baseline.
Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug). Clinical response was determined by the investigator at the PTE visit by assessing whether or not the participant met the clinical outcome of Clinical Success, Clinical Failure, or Indeterminate. Clinical Success was defined as the complete resolution or significant improvement of the baseline AP signs and symptoms at the PTE visit such that no additional antimicrobial therapy is required for the current infection. Clinical Failure was defined as no apparent response to therapy or persistence of signs and symptoms of infection or reappearance of signs and symptoms at or before the PTE visit such that use of additional systemic antimicrobial therapy for the current infection was required or death at or before the PTE visit. The clinical outcome was deemed as Indeterminate when the PTE visit was not completed.
Number of Participants With a Microbiological Response at the PTE Visit (Micro-ITT Population) Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug). Microbiological response was determined programmatically at the PTE visit by assessing whether or not the participant met the microbiological outcome of 'Success', 'Failure', or 'Indeterminate'. Participants were considered to have a microbiological response of 'Success' if the outcomes of each baseline pathogens were eradication at the PTE visit. Participants were considered to have a microbiological response of 'Failure' if the outcome for any pathogen was persistence. Participants were considered to have a microbiological response of 'Indeterminate', if the outcome of at least 1 baseline pathogen was indeterminate and there was no outcome of persistence for any baseline pathogen.
- Secondary Outcome Measures
Name Time Method Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events up to approximately 28 days An adverse event is any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given a study drug or in a clinical study. A treatment-emergent adverse event was defined as any adverse event that newly appeared, increased in frequency, or worsened in severity on or after the initiation of the study drug.
Trial Locations
- Locations (31)
Site 204
🇬🇪Tbilisi, Georgia
Site 305
🇱🇻Rēzekne, Latvia
Site 304
🇱🇻Liepāja, Latvia
Site 507
🇺🇦Zaporizhzhia, Ukraine
Site 301
🇱🇻Daugavpils, Latvia
Site 501
🇺🇦Lviv, Ukraine
Site 201
🇬🇪Tbilisi, Georgia
Site 408
🇷🇺Moscow, Russian Federation
Site 402
🇷🇺Saint Petersburg, Russian Federation
Site 302
🇱🇻Riga, Latvia
Site 504
🇺🇦Kyiv, Ukraine
Site 503
🇺🇦Kyiv, Ukraine
Site 202
🇬🇪Tbilisi, Georgia
Site 203
🇬🇪Tbilisi, Georgia
Site 415
🇷🇺Penza, Russian Federation
Site 412
🇷🇺Saint Petersburg, Russian Federation
Site 502
🇺🇦Chernivtsi, Ukraine
Site 401
🇷🇺Saint Petersburg, Russian Federation
Site 404
🇷🇺Saint Petersburg, Russian Federation
Site 506
🇺🇦Dnipro, Ukraine
Site 406
🇷🇺Saint Petersburg, Russian Federation
Site 403
🇷🇺Saint Petersburg, Russian Federation
Site 407
🇷🇺Rostov-on-Don, Russian Federation
Site 414
🇷🇺Saint Petersburg, Russian Federation
Site 413
🇷🇺Smolensk, Russian Federation
Site 410
🇷🇺Moscow, Russian Federation
Site 409
🇷🇺Krasnoyarsk, Russian Federation
Site 411
🇷🇺Saint Petersburg, Russian Federation
Site 405
🇷🇺Rostov-on-Don, Russian Federation
Site 303
🇱🇻Valmiera, Latvia
Site 505
🇺🇦Kharkiv, Ukraine